Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 6/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421473 | 0.86 | ALOX5 (0.56) | ALOX5MAOBTRPM8L3MBTL1PTGES | |
| SCHEMBL418485 | 0.83 | MAOB (0.44) | ALOX5MAOBL3MBTL1KMT2AMEN1 | |
| SCHEMBL417516 | 0.82 | ALOX5 (0.49) | ALOX5MAOBTRPM8L3MBTL1PTGES | |
| SCHEMBL419285 | 0.82 | FNTA (0.46) | ALOX5KMT2AMEN1PRNPMAPT | |
| SCHEMBL2485581 | 0.81 | ALOX5 (0.47) | ALOX5TRPM8L3MBTL1PTGESKMT2A | |
| SCHEMBL421353 | 0.80 | MCL1 (0.44) | L3MBTL1TRPV1SMN1; SMN2 | |
| SCHEMBL417915 | 0.78 | MAPT (0.45) | TRPM8L3MBTL1KMT2AMEN1PRNP | |
| SCHEMBL419611 | 0.78 | ALOX5 (0.47) | ALOX5MAOBTRPM8L3MBTL1PTGES | |
| SCHEMBL418294 | 0.75 | TRPM8 (0.50) | ALOX5MAOBTRPM8L3MBTL1PTGES | |
| SCHEMBL4786522 | 0.75 | ALOX5 (0.55) | ALOX5TRPM8L3MBTL1PTGESKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376479-B1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO KG (DE) | 2016-03-02 | — | — | EP | disclosed |
| US-8324268-B2 | Substituted furancarboxamides, and use thereof | AICURIS GMBH & CO. KG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-8324268-B2 | Substituted furancarboxamides, and use thereof | AICURIS GMBH & CO. KG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-8324268-B2 | Substituted furancarboxamides, and use thereof | AICURIS GMBH & CO. KG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| WO-2010075957-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AADAC, DDC, TPMT | ALOX5 948/4885MAOB 272/4885TRPM8 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.